← FDA Drug Approvals (Drugs@FDA)

EVDI

NDA · New Drug Application · Sponsor: APOTEX · Approved 2026-05-01

Drug application

FDA Application #

NDA220837

Application type

New Drug Application

Brand name

EVDI

Generic name

Trabectedin

Active ingredients

TRABECTEDIN

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

APOTEX

First approval

2026-05-01

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown